Victory Capital Management Inc Revance Therapeutics, Inc. Transaction History

Victory Capital Management Inc

$99 Billion
Q3 2024

A detailed history of Victory Capital Management Inc transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Victory Capital Management Inc holds 12,073 shares of RVNC stock, worth $31,027. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,073

Previous 12,309 1.92%

Holding current value

$31,027

Previous $31,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	SELL	$2.57 - $2.57 $606 - $606	-236 Reduced 1.92%	12,073 $31,000
Q2 2024 Aug 05, 2024	BUY	$2.34 - $4.73 $4,464 - $9,024	1,908 Added 18.34%	12,309 $31,000
Q1 2024 May 03, 2024	SELL	$4.65 - $9.31 $711 - $1,424	-153 Reduced 1.45%	10,401 $51,000
Q4 2023 Feb 05, 2024	BUY	$5.81 - $11.2 $61,318 - $118,204	10,554 New	10,554 $92,000
Q2 2023 Jul 27, 2023	SELL	$24.7 - $37.61 $847,951 - $1.29 Million	-34,330 Reduced 5.73%	564,355 $14.3 Million
Q1 2023 May 02, 2023	BUY	$18.36 - $35.27 $10.4 Million - $20 Million	567,555 Added 1823.18%	598,685 $19.3 Million
Q4 2022 Feb 10, 2023	SELL	$18.32 - $30.66 $159,365 - $266,711	-8,699 Reduced 21.84%	31,130 $574,000
Q4 2022 Feb 09, 2023	SELL	$18.32 - $30.66 $13,025 - $21,799	-711 Reduced 1.75%	39,829 $735,000
Q3 2022 Nov 02, 2022	BUY	$14.33 - $28.47 $580,938 - $1.15 Million	40,540 New	40,540 $1.09 Million
Q4 2021 Feb 07, 2022	SELL	$12.46 - $27.87 $118,145 - $264,263	-9,482 Closed	0 $0
Q3 2021 Nov 02, 2021	SELL	$25.78 - $33.21 $11,240 - $14,479	-436 Reduced 4.4%	9,482 $264,000
Q2 2021 Aug 03, 2021	SELL	$26.8 - $31.84 $7,611 - $9,042	-284 Reduced 2.78%	9,918 $294,000
Q1 2021 May 04, 2021	BUY	$24.03 - $29.97 $9,395 - $11,718	391 Added 3.99%	10,202 $285,000
Q4 2020 Feb 01, 2021	BUY	$23.41 - $28.34 $11,307 - $13,688	483 Added 5.18%	9,811 $278,000
Q3 2020 Nov 09, 2020	BUY	$23.23 - $34.3 $216,689 - $319,950	9,328 New	9,328 $235,000
Q2 2020 Aug 07, 2020	SELL	$12.6 - $26.55 $100,585 - $211,948	-7,983 Closed	0 $0
Q1 2020 May 04, 2020	SELL	$12.46 - $27.81 $23,225 - $51,837	-1,864 Reduced 18.93%	7,983 $118,000
Q4 2019 Feb 06, 2020	BUY	$11.66 - $20.15 $22,049 - $38,103	1,891 Added 23.77%	9,847 $160,000
Q4 2019 Feb 04, 2020	BUY	$11.66 - $20.15 $18,854 - $32,582	1,617 Added 25.51%	7,956 $178,000
Q3 2019 Nov 12, 2019	BUY	$10.22 - $14.5 $64,784 - $91,915	6,339 New	6,339 $82,000
Q3 2018 Nov 01, 2018	SELL	$23.55 - $30.1 $1.4 Million - $1.78 Million	-59,245 Closed	0 $0
Q2 2018 Aug 02, 2018	SELL	$27.45 - $33.35 $90,585 - $110,055	-3,300 Reduced 5.28%	59,245 $1.63 Million
Q1 2018 May 04, 2018	BUY	$29.15 - $37.4 $199,969 - $256,564	6,860 Added 12.32%	62,545 $1.93 Million
Q4 2017 Feb 01, 2018	BUY	$24.55 - $36.3 $514,813 - $761,210	20,970 Added 60.41%	55,685 $1.99 Million
Q3 2017 Oct 27, 2017	SELL	$22.55 - $28.1 $3,608 - $4,496	-160 Reduced 0.46%	34,715 $956,000
Q2 2017 Aug 07, 2017	BUY	N/A	34,875	34,875 $921,000

Others Institutions Holding RVNC

# of Institutions

234

Shares Held

82.8M

Call Options Held

680K

Put Options Held

896K

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.

Account

Victory Capital Management Inc Revance Therapeutics, Inc. Transaction History